FDA Approves XARELTO — Janssen Pharmaceuticals, Inc.

# FDA Approves Janssen Pharmaceuticals' XARELTO (Rivaroxaban) Oral Anticoagulant Janssen Pharmaceuticals, Inc. received FDA approval for XARELTO (rivaroxaban), an oral anticoagulant expected to compete directly with warfarin and capture significant market share in the growing anticoagulation therapy segment. The approval positions Janssen to capitalize on the shift toward newer direct oral anticoagulants, potentially generating substantial revenue from patients seeking alternatives to traditional blood thinners requiring frequent monitoring.